

(12) UK Patent Application (19) GB (11) 2 196 848 (13) A

(43) Application published 11 May 1988

(21) Application No 8724705

(22) Date of filing 22 Oct 1987

(30) Priority data

(31) 8626098

(32) 31 Oct 1986

(33) GB

(51) INT CL⁴

A61K 9/22 31/485

(52) Domestic classification (Edition J):

A5B 180 294 29Y 800 801 802 803 806 828 829 835
837 840 G LL

U1S 1330 2417 A5B

(71) Applicant

Euroceltique S.A.

(Incorporated in Luxembourg)

122 Boulevard de la Petrusse, Luxembourg

(56) Documents cited

None

(58) Field of search

A5B

Selected US specifications from IPC sub-class A61K

(72) Inventors

Robert Stronech Goldie

Stewart Thomas Leslie

Sandra Therese Antoinette Malkowska

Ronald Brown Miller

(74) Agent and/or Address for Service

Dr S R James,

Napp Pharmaceutical Group, Cambridge Science Park,
Milton Road, Cambridge CB4 4GW

(54) Controlled release hydromorphone composition

(57) A solid controlled release, oral dosage form, the dosage form comprising a therapeutically effective amount of hydromorphone or a salt thereof in a matrix wherein the dissolution rate *in vitro* of the dosage form, when measured by the USP Paddle Method at 100rpm in 900ml aqueous buffer (pH between 1.6 and 7.2) at 37°C is between 12.5% and 42.5% (by weight) hydromorphone release after 1 hour, between 25% and 55% (by weight) hydromorphone released after 2 hours, between 45% and 75% (by weight) hydromorphone released after 4 hours and between 55% and 85% (by weight) hydromorphone released after 6 hours, the *in vitro* release rate being independent of pH between pH 1.6 and 7.2 and chosen such that the peak plasma level of hydromorphone obtained *in vivo* occurs between 2 and 4 hours after administration of the dosage form.

The controlled release form may be either a matrix form of insoluble matrix containing the hydromorphone, or a collection of spherules or granules coated with a suitable slightly permeable but insoluble coating agent and then compressed into a composite matrix.

GB 2 196 848 A

SPECIFICATION

Controlled release hydromorphone composition

- 5 The present invention relates to a solid, controlled release, oral dosage form containing hydromorphone for use in the treatment of moderate to severe pain. 5
- According to the present invention there is provided a solid, controlled release, oral dosage form, the dosage form comprising a therapeutically effective amount of hydromorphone or a salt thereof in a matrix wherein the dissolution rate *in vitro* of the dosage form, when measured by 10 the USP Paddle Method at 100 rpm in 900 ml. aqueous buffer (pH between 1.6 and 7.2) at 37°C is between 12.5 and 42.5% (by wt) hydromorphone released after 1 hour, between 25 and 55% (by wt) hydromorphone released after 2 hours, between 45 and 75% (by wt) hydromorphone released after 4 hours and between 55 and 85% (by wt) hydromorphone released after 6 hours, the *in vitro* release rate being independent of pH between pH 1.6 and 7.2 and 15 such that the peak plasma level of hydromorphone obtained *in vivo* occurs between 2 and 4 hours after administration of the dosage form. 15
- Preferably, the dosage form contains an analgesically effective amount of hydromorphone or a salt thereof.
- USP Paddle Method is the Paddle Method described in US Pharmacopoeia XXI (1985).
- 20 In the present specification, "independent of pH" means that the difference, at any given time, between the amount of hydromorphone released at pH 1.6 and the amount released at any other pH up to, and including, pH 7.2 (when measured *in vitro* using the USP Paddle Method at 100rpm in 900ml aqueous buffer) is 10% (by weight) or less. The amounts released being, in all cases, a mean of at least three experiments. 20
- 25 In the present specification, "peak plasma level of hydromorphone obtained *in vivo*" refers to the maximum mean concentration of hydromorphone found in the plasma of at least six healthy volunteers, when (the volunteers are) subjected to a single dose, pharmacokinetic study. 25
- Preferably the dissolution rate is between 17.5 and 37.5% (by wt) hydromorphone released after 1 hour, between 30 and 50% (by wt) after 2 hours, between 50 and 70% (by wt) after 4 30 hours and between 60 and 80% (by wt) after 6 hours. Most preferably, the dissolution rate is between 22.5 and 32.5% (by wt) hydromorphone released after 1 hour, between 35 and 45% (by wt) after 2 hours, between 55 and 65% (by wt) after 4 hours and between 65 and 75% (by wt) after 6 hours. Preferably the peak plasma level of hydromorphone is obtained *in vivo* between 2.25 and 3.75 hours after administration of the dosage form. 30
- 35 When the hydromorphone is administered as hydromorphone hydrochloride and the method of hydromorphone in plasma analysis is a double antibody radioimmunoassay (as hereinafter described), the peak plasma level of hydromorphone (per ml. of plasma) is preferably between 0.5×10^{-6} and 2.0×10^{-6} , most preferably between 0.5×10^{-6} and 1.5×10^{-6} , of the amount of hydromorphone hydrochloride administered orally. 35
- 40 Thus, if 4mg of hydromorphone hydrochloride is administered, the peak plasma level of hydromorphone is preferably between 2 and 8ngml^{-1} , especially between 2 and 6ngml^{-1} . 40
- When hydromorphone base or a salt other than the hydrochloride is administered, the preferred ratio of drug administered to peak plasma level of hydromorphone must be adjusted according to the molecular weight of the base or salt.
- 45 By keeping within these narrow ranges for *in vitro* dissolution rates, the present inventors have surprisingly found that although the present oral dosage forms give peak plasma levels of hydromorphone between 2 and 4 hours after administration, they still afford therapeutic levels of hydromorphone *in vivo* over at least a 12 hour period, and may therefore be used on a twice daily basis. 45
- 50 In order to obtain a controlled release drug dosage form having at least a 12 hour therapeutic effect, it is usual in the pharmaceutical art to produce a formulation that gives a peak plasma level of the drug between about 4-8 hours after administration (in a single dose study). The present inventors have surprisingly found that, in the case of hydromorphone, a peak plasma level at between 2-4 hours after administration gives at least 12 hours pain relief and, most 55 surprisingly, that the pain relief obtained with such a formulation is greater than that achieved with formulations giving peak plasma levels (of hydromorphone) in the normal period of 1-2 hours after administration. 55
- Furthermore, in the case of the present dosage form, therapeutic levels are generally achieved without concurrent side effects, such as nausea, vomiting, constipation and drowsiness, which 60 are often associated with high blood levels of hydromorphone. There is also evidence to suggest that the use of the present dosage forms leads to a reduced risk of drug addiction. 60
- A further advantage of the present composition, which releases hydromorphone at a rate that is independent of pH between 1.6 and 7.2, is that it avoids dose dumping upon oral administration. In other words, the hydromorphone is released evenly throughout the gastrointestinal tract.
- 65 The present oral dosage form may be presented as, for example, granules, spheroids or 65

pellets in a capsule or in any other suitable solid form. Preferably, however, the oral dosage form is a tablet.

The present oral dosage form preferably contains between 1 and 100 mg, especially between 2 and 50 mg, most especially between 2 and 40mg, of hydromorphone hydrochloride.

5 Alternatively the dosage form may contain molar equivalent amounts of other hydromorphone salts or of the hydromorphone base. 5

The present matrix may be any matrix that affords *in vitro* dissolution rates of hydromorphone within the narrow ranges required and that releases the hydromorphone in a pH independent manner. Preferably the matrix is a controlled release matrix, although normal release matrices 10 having a coating that controls the release of the drug may be used. 10

Suitable materials for inclusion in a controlled release matrix are

(a) Hydrophilic or hydrophobic polymers, such as gums, cellulose ethers, acrylic resins and protein derived materials. Of these polymers, the cellulose ethers, especially hydroxyalkylcelluloses and carboxyalkylcelluloses, are preferred. The oral dosage form may contain between 1% 15 and 80% (by weight) of at least one hydrophilic or hydrophobic polymer. 15

(b) Digestible, long chain (C_8 - C_{50} , especially C_{12} - C_{40}), substituted or unsubstituted hydrocarbons, such as fatty acids, fatty alcohols, glyceryl esters of fatty acids, mineral and vegetable oils and waxes. Hydrocarbons having a melting point of between 25° and 90°C are preferred. Of these long chain hydrocarbon materials, fatty (aliphatic) alcohols are preferred. The oral dosage form 20 may contain up to 60% (by weight) of at least one digestible, long chain hydrocarbon. 20

(c) Polyalkylene glycols. The oral dosage form may contain up to 60% (by weight) of at least one polyalkylene glycol.

One particularly suitable matrix comprises at least one water soluble hydroxyalkyl cellulose, at least one C_{12} - C_{36} , preferably C_{14} - C_{22} , aliphatic alcohol and, optionally, at least one polyalkylene 25 glycol. 25

The at least one hydroxyalkyl cellulose is preferably a hydroxy (C_1 to C_6) alkyl cellulose, such as hydroxypropylcellulose, hydroxypropylmethylcellulose and, especially, hydroxyethyl cellulose. The amount of the at least one hydroxyalkyl cellulose in the present oral dosage form will be determined, *inter alia*, by the precise rate of hydromorphone release required. Preferably how- 30 ever, the oral dosage form contains between 5% and 25%, especially between 6.25% and 15% (by wt) of the at least one hydroxyalkyl cellulose. 30

The at least one aliphatic alcohol may be, for example, lauryl alcohol, myristyl alcohol or stearyl alcohol. In particularly preferred embodiments of the present oral dosage form, however, the at least one aliphatic alcohol is cetyl alcohol or cetostearyl alcohol. The amount of the at 35 least one aliphatic alcohol in the present oral dosage form will be determined, as above, by the precise rate of hydromorphone release required. It will also depend on whether at least one polyalkylene glycol is present in or absent from the oral dosage form. In the absence of at least one polyalkylene glycol, the oral dosage form preferably contains between 20% and 50%, especially between 25% and 45% (by wt) of the at least one aliphatic alcohol. When at least 40 one polyalkylene glycol is present in the oral dosage form, then the combined weight of the at least one aliphatic alcohol and the at least one polyalkylene glycol preferably constitutes between 20% and 50%, especially between 25% and 45% (by wt) of the total dosage form. 40

In the present preferred dosage form, the ratio of the at least one hydroxyalkyl cellulose to the at least one aliphatic alcohol/polyalkylene glycol determines, to a considerable extent, the release 45 rate of the hydromorphone from the formulation. A ratio of the at least one hydroxyalkyl cellulose to the at least one aliphatic alcohol/polyalkylene glycol of between 1:2 and 1:4 is preferred, with a ratio of between 1:3 and 1:4 being particularly preferred. 45

The at least one polyalkylene glycol may be, for example, polypropylene glycol or, which is preferred, polyethylene glycol. The number average molecular weight of the at least one polyal- 50 kylene glycol is preferred between 1000 and 15000 especially between 1500 and 12000. 50

Another suitable controlled release matrix would comprise an alkylcellulose (especially ethyl cellulose), a C_{12} to C_{36} aliphatic alcohol and, optionally, a polyalkylene glycol.

In addition to the above ingredients, a controlled release matrix may also contain suitable quantities of other materials, e.g. diluents, lubricants, binders, granulating aids, colorants, flavo- 55 rants and glidants that are conventional in the pharmaceutical art. 55

As an alternative to a controlled release matrix, the present matrix may be a normal release matrix having a coat that controls the release of the drug. In a particularly preferred embodiment of this aspect of the invention, the present dosage form comprises film coated spheroids containing active ingredient and a non-water soluble spheronising agent. The term spheroid is 60 known in the pharmaceutical art and means a spherical granule having a diameter of between 0.5mm and 2.5mm, especially between 0.5mm and 2mm. 60

The spheronising agent may be any pharmaceutically acceptable material that, together with the active ingredient, can be spheronised to form spheroids. Microcrystalline cellulose is preferred.

65 A suitable microcrystalline cellulose is, for example, the material sold as Avicel PH 101 (Trade 65
BNSDOCID: <GB_2196848A_1>

Mark, FMC Corporation). According to a preferred aspect of the present invention, the film coated spheroids contain between 70% and 99% (by wt), especially between 80% and 95% (by wt), of the spheronising agent, especially microcrystalline cellulose.

- In addition to the active ingredient and spheronising agent, the spheroids may also contain a binder. Suitable binders, such as low viscosity, water soluble polymers, will be well known to those skilled in the pharmaceutical art. However, water soluble hydroxy lower alkyl celluloses, such as hydroxy propyl cellulose, are preferred. Additionally (or alternatively) the spheroids may contain a water insoluble polymer, especially an acrylic polymer, an acrylic copolymer, such as a methacrylic acid-ethyl acrylate copolymer, or ethyl cellulose.
- 10 The spheroids are film coated with a material that permits release of the hydromorphone (or salt) at a controlled rate in an aqueous medium. The film coat is chosen so as to achieve, in combination with the spheroids' other ingredients, the *in-vitro* release rate outlined above (between 12.5% and 42.5% (by wt) release after 1 hour, etc.).
- The film coat will generally include a water insoluble material such as
- 15 (a) a wax, either alone or in admixture with a fatty alcohol,
(b) shellac or zein,
(c) a water insoluble cellulose, especially ethyl cellulose,
(d) a polymethacrylate, especially Eudragit (Trade Mark).
- 20 Preferably, the film coat comprises a mixture of the water insoluble material and a water soluble material. The ratio of water insoluble to water soluble material is determined by, amongst other factors, the release rate required and the solubility characteristics of the materials selected.
- The water soluble material may be, for example, polyvinylpyrrolidone or, which is preferred, a water soluble cellulose, especially hydroxypropylmethyl cellulose.
- 25 Suitable combinations of water insoluble and water soluble materials for the film coat include shellac and polyvinylpyrrolidone or, which is preferred, ethyl cellulose and hydroxypropylmethyl cellulose.
- In order to facilitate the preparation of a solid, controlled release, oral dosage form according to this invention there is provided, in a further aspect of the present invention, a process for the
- 30 preparation of a solid, controlled release, oral dosage form according to the present invention comprising incorporating hydromorphone or a salt thereof in a controlled release matrix. Incorporation in the matrix may be effected, for example, by (a) forming granules comprising at least one water soluble hydroxyalkyl cellulose and hydromorphone or a hydromorphone salt,
(b) mixing the hydroxyalkyl cellulose containing granules with at least one C₁₂-C₃₆ aliphatic
- 35 alcohol, and
(c) optionally, compressing and shaping the granules.
- Preferably, the granules are formed by wet granulating the hydroxyalkyl cellulose/hydromorphone with water. In a particularly preferred embodiment of this process, the amount of water added during the wet granulation step is preferably between 1.5 and 5 times, especially between
- 40 1.75 and 3.5 times, the dry weight of the hydroxyalkyl cellulose.
- The present solid, controlled release, oral dosage form may also be prepared, in the form of film coated spheroids, by
- (a) blending a mixture comprising hydromorphone or a hydromorphone salt and a non-water soluble spheronising agent,
- 45 (b) extruding the blended mixture to give an extrudate,
(c) spheronising the extrudate until spheroids are formed, and
(d) coating the spheroids with a film coat.
- The present solid, controlled release, oral dosage form and processes for its preparation will now be described by way of example only.
- 50
- Example 1**
- Hydromorphone hydrochloride (4.0gm) was wet granulated with lactose monohydrate (167.0gm) and hydroxyethyl cellulose (40.0gm; Natrosol 250 HX, Trade Mark) and the granules were sieved through a 12 mesh screen. The granules were then dried in a Fluid Bed Dryer at
- 55 50°C and passed through a 16 mesh screen.
- To the warmed hydromorphone containing granules was added molten cetostearyl alcohol (120.0gm) and the whole was mixed thoroughly. The mixture was allowed to cool in the air, regranulated and sieved through a 16 mesh screen.
- Purified Talc (6.0gm) and magnesium stearate (3.0gm) were then added and mixed with the
- 60 granules. The granules were then compressed into 1000 tablets each containing,

	<u>mg/tablet</u>	
	4.0	
Hydromorphone Hydrochloride		
5 Lactose Monohydrate	167.0	5
Hydroxyethylcellulose	40.0	
Cetostearyl alcohol	120.0	
10 Purified Talc	6.0	10
Magnesium stearate	3.0	

15

Example 2

The procedure of Example 1 was followed, but with reduced quantities of cellulose and fatty alcohol, to give 1000 tablets each containing,

	<u>mg/tablet</u>	
20	4.0	20
Hydromorphone Hydrochloride		
Anhydrous Lactose	167.0	
25 Hydroxyethylcellulose	30.0	25
Cetostearyl Alcohol	90.0	
Purified Talc	6.0	
30 Magnesium Stearate	3.0	30

Example 3

Hydromorphone hydrochloride (4.0gm) was wet granulated with lactose monohydrate (30.0gm) 35 hydroxyethyl cellulose (10.0gm; Natrosol 250 HX, Trade Mark) and methacrylic acid copolymer (30.0gm, Eudragit L-100-55; Trade Mark) and the granules were sieved through a 12 mesh screen. The granules were then dried in a Fluid Bed Dryer at 50°C and passed through a 16 mesh screen.

To the warmed hydromorphone containing-granules was added molten cetostearyl alcohol 40 (30.0gm) and the whole was mixed thoroughly. The mixture was allowed to cool in the air, regranulated and sieved through a 16 mesh screen.

The granules were then compressed into 1000 tablets each containing,

	<u>mg/tablet</u>	
45	4.0	45
Hydromorphone Hydrochloride		
Lactose Monohydrate	30.0	
Hydroxyethylcellulose	10.0	
50 Methacrylic Acid Copolymer	30.0	50
Cetostearyl alcohol	30.0	

55

Example 4

Hydromorphone hydrochloride (50g) microcrystalline cellulose (Avicel PH101, 440g) and hydroxypropylmethyl cellulose (Methocel E15, 10g) were dry mixed. Water (350ml) was then added and the mixture was granulated. The granulated mass was extruded through a 1mm 60 cylinder and the extrudate was spheronised. The resultant spheroids were dried at 60°C in a fluid bed drier. The moisture content of the dried spheroids was found to be 4.3% w/w (Karl-Fischer). The dried spheroids were then sieved and the sieve fraction between 1.0mm and 1.4mm was retained.

The spheroids were coated with a film coat, having the formulation given below, to a level of

65 15% w/w.

65

Film Coat Formulation

5	Ethylcellulose N10	4.0% w/v	5
	Hydroxypropylmethylcellulose (Methocel E15)	1.0% w/v	
	Propylene glycol BP	0.5% w/v	
10	Opaspray K-1-4132	3.0% w/v	10
	Methanol	60.0% v/v	
	Dichloromethane	to 100.0% v/v	

15 15

In Vitro Dissolution Studies

In vitro dissolution studies were conducted on tablets prepared as described in Example 1. The dissolution method was the USP Paddle Method described in US Pharmacopoeia XXI (1985). The paddle speed was 100 rpm, the temperature was 37°C and the medium was 900ml water. Results are given in Table 1.

TABLE 1

25			25
	<u>Time (hr)</u>	<u>wt. % Hydromorphone released</u>	
30	1	28.3	30
	2	41.8	
	3	51.5	
35	4	59.5	35
	5	65.5	
	6	70.0	
40	7	75.0	40
	8	80.0	

In vitro dissolution studies were conducted on tablets prepared as described in Example 2. The dissolution method was the USP Paddle Method described in US Pharmacopoeia XXI (1985). The paddle speed was 100rpm, the temperature was 37°C and the medium was an aqueous buffer (pH 6.5).

Results are given in Table 2.

TABLE 2

<u>Time (hr)</u>	<u>wt. % Hydromorphone released</u>	
1	26	
2	41	
3	52	
4	60	
5	67	
6	74	
7	79	
8	83	

In vitro dissolution studies were conducted on tablets prepared as described in Example 3. The dissolution method was the USP Paddle Method described in US Pharmacopoeia XXI (1985). The paddle speed was 100 rpm, the temperature was 37°C and the medium was 900 ml water.

Results are given in Table 3.

Table 3

<u>Time (hr)</u>	<u>wt. % Hydromorphone released</u>	
1	35	
2	50	
3	59	
4	66	
5	72	
6	76	
7	80	

In vitro dissolution studies were conducted on tablets prepared as described in Example 1. The dissolution method was the USP Paddle Method described in US Pharmacopoeia XXI (1985). The paddle speed was 100rpm, the temperature was 37°C and the media were USP Buffers (pH 1.6, 6.5 and 7.2).

Results are given in Table 4.

TABLE 4

5	<u>Time (hr)</u>	<u>wt% Hydromorphone released</u>			5
		<u>pH 1.6</u>	<u>pH 6.5</u>	<u>pH 7.2</u>	
10					10
	1	34.7	36.0	36.6	
	2	48.1	51.2	51.0	
15	3	58.5	61.7	61.1	15
	4	66.5	70.0	69.8	
	6	79.1	81.8	81.8	
20	8	88.2	90.6	90.7	20
	10	95.1	97.7	99.2	
	12	100.0	100.0	100.0	
25					25

Clinical Studies

A. A single dose, randomised, comparative, pharmacokinetic study was conducted on 4 subjects employing,

- 30 i) A hydromorphone hydrochloride tablet prepared as described in Example 1, (a 4mg dose), and

ii) A normal release hydromorphone hydrochloride tablet (Dilaudid; Trade Mark; a 4mg dose).

Analysis of the plasma samples for hydromorphone was performed by a double antibody radioimmunoassay.

- 35 Plasma was assayed by incubating first with ¹²⁵Iodohydromorphone and antimorphine antiserum (raised in goats against a 6-hemisuccinyl morphine-BSA conjugate), and subsequently with a solid phase bound antiserum suspension (Sac Cel, anti sheep/goat, Trade Mark). Following the addition of water the samples were centrifuged and the supernatant was removed. The radioactivity in the remaining pellet was counted on a multi-gamma counter for 60 seconds.

40 Results are given in Table 5.

TABLE 5

5	Time (hr)	Mean Plasma Conc. (ng/ml ⁻¹)		5
		<u>Example 1</u>	<u>Dilaudid</u>	
10	0.50	0.9	9.4	10
	1.0	3.8	8.8	
	1.50	4.4	8.6	
15	2.0	4.2	7.8	15
	2.5	4.5	7.9	
	3.0	4.8	6.2	
20	4.0	4.3	3.5	20
	6.0	3.0	3.2	
	8.0	1.4	1.6	
25	10.0	1.6	1.0	25
	12.0	1.0	0.5	
30	24.0	1.1	0.5	30

B. A single dose, randomised, comparative, pharmacokinetic study was conducted on 12 subjects employing.

35 and i) A hydromorphone hydrochloride tablet prepared as described in Example 1 (a 4mg dose),

ii) A normal release hydromorphone hydrochloride tablet (Dilaudid; Trade Mark; a 4mg dose).

Analysis of the plasma samples for hydromorphone was performed by the radioimmunoassay described in study A. Results are given in Table 6.

TABLE 6

5	Time (hr)	Mean Plasma Conc. (ng/ml)		5
		Example 1	Dilaudid	
10	0.5	2.3	5.8	10
	1.0	3.7	7.0	
	1.5	3.9	7.3	
15	2.0	4.4	6.4	15
	2.5	4.5	5.9	
	3.0	4.3	5.3	
20	4.0	4.3	4.4	20
	6.0	3.7	3.1	
	8.0	3.1	2.5	
25	10.0	2.5	2.3	25
	12.0	2.1	2.0	
	24.0	1.4	1.1	

30

C. A single dose, comparative, pharmacokinetic study was conducted on 24 subjects employing
 (i) A hydromorphone hydrochloride tablet prepared as described in Example 1 (a 4mg dose)

and,

(ii) A normal release hydromorphone hydrochloride tablet (Dilaudid, Trade Mark, a 4mg dose).

35

Analysis of the plasma samples for hydromorphone was performed and the results are given
 in Table 7.

35

TABLE 7

5	Time (hr)	Mean Plasma Conc. (ng/ml)		5
		Example 1	Dilaudid	
10	0	0.12	0.15	10
	0.5	0.57	2.68	
	1.0	0.67	2.23	
15	1.5	0.74	1.78	15
	2.0	0.75	1.47	
	2.5	0.72	1.11	
20	3.0	0.69	0.94	20
	3.5	0.65	0.82	
	4.0	0.59	0.77	
25	5.0	0.71	0.53	25
	6.0	0.59	0.40	
	8.0	0.40	0.29	
30	10.0	0.49	0.26	30

CLAIMS

- 35 1. A solid, controlled release, oral dosage form, the dosage form comprising a therapeutically effective amount of hydromorphone or a salt thereof in a matrix wherein the dissolution rate in *vitro* of the dosage form, when measured by the USP Paddle Method at 100 rpm in 900ml aqueous buffer (pH between 1.6 and 7.2) at 37°C is between 12.5% and 42.5% (by wt) hydromorphone released after 1 hour, between 25% and 55% (by wt) hydromorphone released after 2 hours, between 45% and 75% (by wt) hydromorphone released after 4 hours and between 55% and 85% (by wt) hydromorphone released after 6 hours, the *in vitro* release rate being independent of pH between 1.6 and 7.2 and chosen such that the peak plasma level of hydromorphone obtained *in vivo* occurs between 2 and 4 hours after administration of the dosage form.
- 40 2. A dosage form according to claim 1 wherein the *in vitro* dissolution rate is between 17.5% and 37.5% (by weight) hydromorphone released after 1 hour, between 30% and 50% (by weight) hydromorphone released after 2 hours, between 50% and 70% (by weight) hydromorphone released after 4 hours and between 60% and 80% (by weight) hydromorphone released after 6 hours.
- 50 3. A dosage form according to claim 2 wherein the *in vitro* dissolution rate is between 22.5% and 32.5% (by weight) hydromorphone released after 1 hour, between 35% and 45% (by weight) hydromorphone released after 2 hours, between 55% and 65% (by weight) hydromorphone released after 4 hours and between 65% and 75% (by weight) hydromorphone released after 6 hours.
- 55 4. A dosage form according to any one of claims 1 to 3 wherein the peak plasma level of hydromorphone occurs between 2.25 and 3.75 hours after administration of the dosage form.
5. A dosage form according to any one of claims 1 to 4 wherein a therapeutically effective amount of a hydromorphone salt comprises between 2 and 50mg of hydromorphone hydrochloride.
- 60 6. A dosage form according to claim 5 wherein a therapeutically effective amount of a hydromorphone salt comprises between 2 and 40mg of hydromorphone hydrochloride.
7. A dosage form according to any one of claims 1 to 6 wherein the matrix comprises a controlled release matrix comprising at least one water soluble hydroxyalkylcellulose, at least one C₁₂ to C₃₆ aliphatic alcohol and, optionally, at least one polyalkylene glycol.
- 65 8. A dosage form according to claim 7 wherein the at least one water soluble hydroxyalkylcel-

lulose comprises a hydroxy C₁-C₆ alkyl cellulose.

9. A dosage form according to of claim 8 wherein the at least one hydroxyalkyl cellulose comprises hydroxypropyl cellulose, hydroxypropylmethylcellulose or hydroxyethylcellulose.

10. A dosage form according to claim 9 wherein the at least one hydroxyalkylcellulose
5 comprises hydroxyethylcellulose.

11. A dosage form according to any one of claims 7 to 10 wherein the dosage form contains between 5% and 25% (by weight) of the at least one hydroxyalkylcellulose.

12. A dosage form according to claim 11 wherein the dosage form contains between 6.25% and 15% (by weight) of the at least one hydroxyalkylcellulose.

10 13. A dosage form according to any one of claims 7 to 12 wherein the aliphatic alcohol comprises a C₁₄ to C₂₂ aliphatic alcohol.

14. A dosage form according to any one of claims 7 to 12 wherein the aliphatic alcohol comprises lauryl alcohol, myristyl alcohol, stearyl alcohol or cetostearyl alcohol.

15 15. A dosage form according to claim 14 wherein the aliphatic alcohol comprises cetyl alcohol or cetostearyl alcohol.

16. A dosage form according to any one of claims 7 to 15 wherein the dosage form contains between 20% and 50% (by weight) of the at least one fatty alcohol or of the at least one fatty alcohol and the at least one polyalkylene glycol.

20 17. A dosage form according to claim 16 wherein the dosage form contains between 25% and 45% (by weight) of the at least one fatty alcohol or of the at least one fatty alcohol and the at least one polyalkylene glycol.

18. A dosage form according to any one of claims 7 to 17 wherein the ratio of the at least one hydroxyalkylcellulose to the at least one aliphatic alcohol/polyalkylene glycol is between 1:2 and 1:4.

25 19. A dosage form according to claim 18 wherein the ratio is between 1:3 and 1:4.

20. A dosage form according to any one of claims 1 to 6 in the form of film coated spheroids wherein the spheroid matrix comprises a non-water soluble spheronising agent.

21. A dosage form according to claim 20 wherein the spheroid matrix comprises microcrystalline cellulose.

30 22. A dosage form according to claim 21 wherein the spheroid matrix comprises microcrystalline cellulose and a water insoluble polymer.

23. A solid, controlled release, oral dosage form according to claim 1 substantially as hereinbefore described with particular reference to any one of the Examples 1 to 4.

35 24. A process for the preparation of a solid, controlled release, oral dosage form comprising incorporating a therapeutically effective amount of hydromorphone or a salt thereof in a matrix wherein the dissolution rate *in vitro* of the dosage form, when measured by the USP Paddle Method at 100 rpm in 900ml aqueous buffer (pH between 1.6 and 7.2) at 37°C is between

12.5% and 42.5% (by wt) hydromorphone released after 1 hour, between 25% and 55% (by wt) hydromorphone released after 2 hours, between 45% and 75% (by wt) hydromorphone released after 4 hours and between 55% and 85% (by wt) hydromorphone released after 6 hours, the *in vitro* release rate being independent of pH between pH 1.6 and 7.2 and chosen such that the peak plasma level of hydromorphone obtained *in vivo* occurs between 2 and 4 hours after administration of the dosage form.

25. A process according to claim 24 comprising,

45 (a) wet granulating at least one water soluble hydroxyalkylcellulose salt to form granules, (b) mixing the hydroxyalkylcellulose containing granules with at least one C₁₂-C₃₆ aliphatic alcohol, and

(c) optionally, compressing and shaping the granules.

50 26. A process according to claim 25 wherein the at least one water soluble hydroxyalkylcellulose and the hydromorphone or the salt thereof are wet granulated with water, the weight ratio of the water to the dry weight of the at least one water soluble hydroxyalkylcellulose being between 1.5 to 1 and 5 to 1.

27. A process according to claim 25 wherein the weight ratio of the water to the dry weight of the at least one water soluble hydroxyalkylcellulose is between 1.75 to 1 and 3.5 to 1.

55 28. A process according to claim 24 comprising blending a mixture comprising hydromorphone or a salt thereof and a non-water soluble spheronising agent, extruding the blended mixture to give an extrudate, spheronising the extrudate until spheroids are formed, and coating the spheroids with a film coat.

29. A process according to claim 28 wherein the non-water soluble spheronising agent
60 comprises microcrystalline cellulose.

30. A process for the preparation of a solid, controlled release, oral dosage form according to claim 24 substantially as hereinbefore described with particular reference to any one of the Examples 1 to 4.

Published 1988 at The Patent Office, State House, 66/71 High Holborn, London WC1R 4TP. Further copies may be obtained from The Patent Office, Sales Branch, St Mary Cray, Orpington, Kent BR5 3RD. Printed by Burgess & Son (Abingdon) Ltd. Con. 1/87.

